HC Wainwright & Co. Reiterates Buy on Vor Biopharma, Maintains $31 Price Target
Benzinga Newsdesk 5 months ago
NewsPrice TargetReiterationAnalyst Ratings
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Vor Biopharma (NASDAQ:VOR) with a Buy and maintains $31 price target.
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Vor Biopharma (NASDAQ:VOR) with a Buy and maintains $31 price target.